skip to Main Content

Robard Corporation Announces the Launch of Biocare®, the First Dietary Beverage Designed Specifically for People Using GLP-1 Weight Loss Medications

Subscribe to The Robard Blogs:

Robard Corporation Announces the Launch of Biocare®, the First Dietary Beverage Designed Specifically for People Using GLP-1 Weight Loss Medications

MOUNT LAUREL, NJ, March 7, 2024 — Robard Corporation, a leading provider of obesity treatment programs and scientifically-designed nutrition products for the medical community since 1976, today announced the launch of Biocare, a direct-to-consumer dietary beverage for people using glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss, such as Wegovy® or Ozempic® (semaglutide), as well as Mounjaro® or Zepbound® (tirzepatide).

Biocare’s patent-pending formula — including scientifically-researched ingredients that focus on the digestive and nutritional impact of anti-obesity medications — is designed for individuals taking GLP-1 medications to help reduce common side effects, including nausea, bloating, constipation, diarrhea, lack of energy, in addition to helping to compensate for the loss of muscle mass.

Studies on these medications highlight factors that negatively impact nutritional health and well-being, including loss of lean body weight (muscle mass), gastrointestinal side effects, reduced intake of protein, fiber and essential micronutrients, and significant decreases in daily calorie intake by as much as 40-50%.

To counteract nutritional deficiencies and ensure daily nutritional requirements are met, each naturally flavored and sweetened serving of Biocare includes 20 grams of protein, 26 vitamins and minerals, probiotics and prebiotic fibers, bioactive anti-nausea compounds, healthy fats, and more. It is recommended that people using GLP-1 medications consume two (2) servings of Biocare per day.

“While effective for blood glucose control and weight loss, GLP-1 weight loss medications can also significantly alter diet quality and compromise nutritional wellness,” said Robert Schwartz, president and founder of Robard Corporation. “The impact of reduced diet quality can have short-term and long-term consequences on metabolism and overall health for weight loss patients. Biocare helps ensure essential dietary requirements are available when taking GLP-1 medications by utilizing specialized nutritional ingredients to help reduce side effects and preserve lean muscle mass.”

The Biocare dietary beverage is available in Chocolate and Mixed Fruit flavors, and can be purchased by consumers at www.BiocareNutrition.com.

###

About Robard Corporation:

Robard Corporation, a privately-owned company headquartered in New Jersey, provides health care professionals with turnkey solutions to offer medically-supervised obesity treatment to patients. With over 45 years of expertise in the weight loss and management industry, Robard’s evidence-based programs are complemented by scientifically-designed nutrition products and best-in-class business services. These comprehensive offerings empower physicians, surgeons, and hospitals to effectively address patients with obesity and related chronic conditions. For more information, please visit www.Robard.com.

Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Novo Nordisk is a registered trademark of Novo Nordisk A/S.

Mounjaro® and Zepbound® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Back To Top